Premium
Plasminogen activator inhibitor‐1 is an independent diagnostic marker as well as severity predictor of hepatic veno‐occlusive disease after allogeneic bone marrow transplantation in adults conditioned with busulphan and cyclophosphamide
Author(s) -
Lee JeHwan,
Lee KyooHyung,
Lee JungHee,
Kim Shin,
Seol Miee,
Park ChanJeoung,
Chi HyunSook,
Kang Weechang,
Kim Seung Taik,
Kim WooKun,
Lee JungShin
Publication year - 2002
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.2002.03748.x
Subject(s) - medicine , gastroenterology , hepatic veno occlusive disease , cyclophosphamide , plasminogen activator , bilirubin , bone marrow , transplantation , logistic regression , surgery , immunology , chemotherapy , hematopoietic stem cell transplantation
Summary. We attempted to identify the diagnostic markers and severity predictors of hepatic veno‐occlusive disease (VOD) in 115 adult patients who were uniformly conditioned with busulphan and cyclophosphamide and who underwent allogeneic bone marrow transplantation (BMT). A diagnosis of VOD was made according to clinical criteria. Severity of VOD was classified as mild, moderate or severe. Various haemostatic parameters were determined at five time points (d −7, 0, 7, 14 and 21). Using clinical and haemostatic parameters, we developed multivariate models to identify diagnostic markers as well as severity predictors of VOD. Of the 115 patients included in the study, 50 (43·5%) developed VOD. Twenty‐nine had mild VOD, 13 moderate and 8 severe. Multiple logistic regression models showed that plasminogen activator inhibitor‐1 (PAI‐1) antigen ( P = 0·029), percentage change of body weight ( P = 0·001) and bilirubin ( P < 0·001) were independent marker variables for the occurrence of VOD, and PAI‐1 antigen ( P = 0·030) and bilirubin ( P = 0·049) were independent marker variables for the occurrence of severe VOD. Our study suggests that PAI‐1 antigen can be used as a diagnostic marker as well as a severity predictor of VOD after allogeneic BMT.